MiR-224 promotes the chemoresistance of human lung adenocarcinoma cells to cisplatin via regulating G1/S transition and apoptosis by targeting p21WAF1/CIP1
暂无分享,去创建一个
R. Wang | H. Wang | Z-X Wang | H Wang | L-J Zhu | Y-C Yang | R Wang | Y-C Yang | Z-X Wang | L. Zhu | L-J Zhu | Hui-Fu Wang | Lingjun Zhu | Yang Yang | Zhiqiang Wang | Rongliang Wang
[1] E. Seim,et al. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. , 1989, Journal of clinical pathology.
[2] Bing Feng,et al. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. , 2012, Cancer letters.
[3] W. Zou. Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.
[4] Xi Chen,et al. Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.
[5] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[6] P. Kuppen,et al. Natural killer cells: from "disturbing" background to central players of immune responses. , 2005, Molecular immunology.
[7] Zhao-You Tang,et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] H. Wiendl,et al. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? , 2007, Seminars in cancer biology.
[9] R. Rosell,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. , 2002, Lung cancer.
[10] Jia Yu,et al. MicroRNA-98 sensitizes cisplatin-resistant human lung adenocarcinoma cells by up-regulation of HMGA2. , 2013, Die Pharmazie.
[11] B. Tait,et al. HLA expression and cancer--14th IHIWS immunohistochemistry quality control exercise exchange results. , 2007, Tissue antigens.
[12] Christophe Benoist,et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. , 2007, Immunity.
[13] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[14] R. Rouzier,et al. HLA‐G1 and HLA‐G5 active dimers are present in malignant cells and effusions: The influence of the tumor microenvironment , 2012, European journal of immunology.
[15] Eddie Reed,et al. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). , 2004, Oncology reports.
[16] H. Putter,et al. HLA-E and HLA-G Expression in Classical HLA Class I-Negative Tumors Is of Prognostic Value for Clinical Outcome of Early Breast Cancer Patients , 2010, The Journal of Immunology.
[17] D. Mu,et al. MicroRNAs and lung cancers: from pathogenesis to clinical implications , 2012, Frontiers of Medicine.
[18] S. Lu,et al. Upregulation of microRNA-224 confers a poor prognosis in glioma patients , 2013, Clinical and Translational Oncology.
[19] R. Kobayashi,et al. Pivotal Role of the Cyclin-dependent Kinase Inhibitor p21WAF1/CIP1 in Apoptosis and Autophagy* , 2008, Journal of Biological Chemistry.
[20] A. Chung,et al. MicroRNA‐224 is up‐regulated in hepatocellular carcinoma through epigenetic mechanisms , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Gavin P Dunn,et al. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.
[22] Yi Tie,et al. miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. , 2012, Lung Cancer.
[23] H. Friess,et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer , 2012, British Journal of Cancer.
[24] D. Yin,et al. CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes , 2011, Breast Cancer Research and Treatment.
[25] L. Schiffmann,et al. Is the lymph node ratio superior to the Union for International Cancer Control (UICC) TNM system in prognosis of colon cancer? , 2013, World Journal of Surgical Oncology.
[26] K. Chayama,et al. Involvement of microRNA‐224 in cell proliferation, migration, invasion, and anti‐apoptosis in hepatocellular carcinoma , 2013, Journal of gastroenterology and hepatology.
[27] B. Chauffert,et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.
[28] B. Chauffert,et al. Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells , 2008, Clinical Cancer Research.
[29] Federica Cavallo,et al. 2011: the immune hallmarks of cancer , 2011, Cancer Immunology, Immunotherapy.
[30] N. Zeps,et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] W. De,et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14) , 2011, Oncogene.
[32] Hui Wang,et al. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer , 2013, Diagnostic Pathology.
[33] Yanqing Ding,et al. microRNA-224 Promotes Cell Proliferation and Tumor Growth in Human Colorectal Cancer by Repressing PHLPP1 and PHLPP2 , 2013, Clinical Cancer Research.
[34] Hein Putter,et al. FoxP3- and CD8-positive Infiltrating Immune Cells Together Determine Clinical Outcome in Colorectal Cancer , 2011, Cancer Microenvironment.
[35] Hua-sheng Xiao,et al. miRNAs modulate the drug response of tumor cells , 2009, Science in China Series C: Life Sciences.
[36] H. Putter,et al. The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer , 2010, Clinical Cancer Research.
[37] Long-Bang Chen,et al. MicroRNA‐200b reverses chemoresistance of docetaxel‐resistant human lung adenocarcinoma cells by targeting E2F3 , 2012, Cancer.
[38] Kuo-Bin Li,et al. Profiling MicroRNA Expression in Hepatocellular Carcinoma Reveals MicroRNA-224 Up-regulation and Apoptosis Inhibitor-5 as a MicroRNA-224-specific Target* , 2008, Journal of Biological Chemistry.
[39] Wei De,et al. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549) , 2011, Journal of experimental & clinical cancer research : CR.
[40] C. Sen,et al. miRNA in Wound Inflammation and Angiogenesis , 2012, Microcirculation.
[41] A. Martayan,et al. HLA-A, -B, -C Expression in Colon Carcinoma Mimics That of the Normal Colonic Mucosa and is Prognostically Relevant , 2007, The American journal of surgical pathology.
[42] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[43] J. Amiel,et al. miRNA, development and disease. , 2012, Advances in genetics.
[44] T. Curiel,et al. Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.
[45] G. Hannon,et al. Control of translation and mRNA degradation by miRNAs and siRNAs. , 2006, Genes & development.
[46] N. Restifo,et al. Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.
[47] Xianghuo He,et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region , 2010, Oncogene.
[48] J. Yun,et al. MiR-663, a microRNA targeting p21WAF1/CIP1, promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma , 2012, Oncogene.
[49] Hein Putter,et al. Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.
[50] Hong Yang,et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer , 2007, Modern Pathology.
[51] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[52] M. Smyth,et al. Immune surveillance of tumors. , 2007, The Journal of clinical investigation.
[53] J. Galon,et al. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.
[54] E. Thiel,et al. Journal of Translational Medicine in Situ Analysis of Foxp3+ Regulatory T Cells in Human Colorectal Cancer , 2006 .
[55] H. Putter,et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis , 2004, Laboratory Investigation.
[56] G. Fleuren,et al. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression , 2007, BMC Cancer.
[57] Yingjun Zhao,et al. MicroRNA-423 promotes cell growth and regulates G(1)/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. , 2011, Carcinogenesis.
[58] R. Tollenaar,et al. Natural killer cells infiltrating colorectal cancer and MHC class I expression. , 2005, Molecular immunology.
[59] R. Schreiber,et al. Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.
[60] Shuji Ogino,et al. Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review , 2010, The Journal of pathology.
[61] C. Yau,et al. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations , 2013, The American Journal of Gastroenterology.
[62] G. Ferrara,et al. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines. , 2005, Human immunology.
[63] Ting He,et al. p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell , 2010, BMC Cancer.
[64] A. Warth,et al. Tumor–microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma , 2013, Genes, chromosomes & cancer.
[65] Zhimin Zhang,et al. MicroRNA‐224 is upregulated in HepG2 cells and involved in cellular migration and invasion , 2010, Journal of gastroenterology and hepatology.
[66] I. Ellis,et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis , 2006, International journal of cancer.
[67] Donald C. Chang,et al. The MicroRNA (miRNA): Overview of the RNA Genes that Modulate Gene Function , 2007, Molecular biotechnology.
[68] D. Geraghty,et al. Analysis of HLA-E expression in human tumors , 2003, Immunogenetics.
[69] B. Hantash,et al. Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies. , 2012, Tissue antigens.
[70] R. Schreiber,et al. The three Es of cancer immunoediting. , 2004, Annual review of immunology.
[71] Stephen B Fox,et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] Liping Xie,et al. Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. , 2008, Cancer letters.
[73] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[74] S. Dahrouge,et al. Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms. , 2007, Cancer treatment reviews.
[75] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[76] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[77] Huiyong Shen,et al. MicroRNA-224 targets RKIP to control cell invasion and expression of metastasis genes in human breast cancer cells. , 2012, Biochemical and biophysical research communications.
[78] M. Holcik,et al. Translation control in apoptosis. , 2012, Experimental oncology.
[79] Shengdian Wang,et al. Accumulation of Foxp3+ T Regulatory Cells in Draining Lymph Nodes Correlates with Disease Progression and Immune Suppression in Colorectal Cancer Patients , 2010, Clinical Cancer Research.
[80] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[81] A. Martayan,et al. HLA-E: Strong Association with β2-Microglobulin and Surface Expression in the Absence of HLA Class I Signal Sequence-Derived Peptides1 , 2008, The Journal of Immunology.
[82] G. Fogel,et al. From pluripotency to islets: miRNAs as critical regulators of human cellular differentiation. , 2012, Advances in genetics.
[83] I. Talbot,et al. The inflammatory response within Dukes’ B colorectal cancers: implications for progression of micrometastases and patient survival , 2000, American Journal of Gastroenterology.
[84] Hong Yang,et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. , 2007, Lung cancer.
[85] Masao Tanaka,et al. Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer , 2010, Cancer Immunology, Immunotherapy.
[86] Jing Xian Lee,et al. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. , 2006, Biochemical and biophysical research communications.
[87] Thomas Tuschl,et al. MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.
[88] Thomas Tuschl,et al. miRNAs in human cancer , 2011, The Journal of pathology.
[89] J Ma,et al. MicroRNA and drug resistance , 2010, Cancer Gene Therapy.
[90] G. Russ,et al. The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. , 2004, Human immunology.
[91] F. Ghiringhelli,et al. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer , 2011, Cancer Immunology, Immunotherapy.
[92] De-Pei Liu,et al. MicroRNAs: key participants in gene regulatory networks. , 2003, Current opinion in chemical biology.
[93] Anindya Dutta,et al. p21 in cancer: intricate networks and multiple activities , 2009, Nature Reviews Cancer.
[94] Michael M Gottesman,et al. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.
[95] S. Hirohashi,et al. Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.
[96] M. Kloor,et al. Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial , 2012, British Journal of Cancer.
[97] R. Place,et al. Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells , 2008, Molecular Cancer Therapeutics.
[98] K. Koretz,et al. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. , 1991, Cancer research.
[99] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[100] J. Bertino,et al. Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. , 1997, Cancer research.
[101] Hong Yang,et al. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. , 2007, American journal of clinical pathology.
[102] N. Rouas-Freiss,et al. Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. , 2003, Human immunology.
[103] I. Cascorbi,et al. miRNAs as mediators of drug resistance. , 2012, Epigenomics.
[104] M. Joshi,et al. Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.
[105] Ping Yang,et al. Lung cancer in China: challenges and interventions. , 2013, Chest.
[106] Ying Huang,et al. Anti-cancer effects of p21WAF1/CIP1 transcriptional activation induced by dsRNAs in human hepatocellular carcinoma cell lines , 2011, Acta Pharmacologica Sinica.
[107] S. Fox,et al. Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients , 2009, Clinical Cancer Research.
[108] Hong Yang,et al. Expression of Human Leukocyte Antigen G (HLA-G) Correlates with Poor Prognosis in Gastric Carcinoma , 2007, Annals of Surgical Oncology.